280 related articles for article (PubMed ID: 8638606)
1. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
[TBL] [Abstract][Full Text] [Related]
2. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
3. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
Randi ML; Fabris F; Ruzzon E; Pacquola E; Cella G; Girolami A
Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348
[TBL] [Abstract][Full Text] [Related]
4. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S.
De Stefano V; Leone G; Mastrangelo S; Tripodi A; Rodeghiero F; Castaman G; Barbui T; Finazzi G; Bizzi B; Mannucci PM
Thromb Haemost; 1994 Sep; 72(3):352-8. PubMed ID: 7855783
[TBL] [Abstract][Full Text] [Related]
5. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.
Falanga A; Marchetti M; Barbui T; Smith CW
Semin Hematol; 2005 Oct; 42(4):239-47. PubMed ID: 16210037
[TBL] [Abstract][Full Text] [Related]
7. [Hereditary deficiency of antithrombin III, protein C, protein S and factor XII in 121 patients with venous or arterial thrombosis].
Miljić P; Rolović Z; Elezović I; Antunović P; Stanojević M; Colović M
Srp Arh Celok Lek; 1999; 127(1-2):21-7. PubMed ID: 10377836
[TBL] [Abstract][Full Text] [Related]
8. Sex and age as prognostic factors in essential thrombocythemia.
Randi ML; Fabris F; Rossi C; Tison T; Barbone E; Girolami A
Haematologica; 1992; 77(5):402-4. PubMed ID: 1483589
[TBL] [Abstract][Full Text] [Related]
9. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
Landolfi R; Cipriani MC; Novarese L
Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
[TBL] [Abstract][Full Text] [Related]
11. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera].
Nagai M; Tasaka T; Kamano H; Ohnishi H; Taoka T; Ikeda K; Kubota Y; Tanaka T; Irino S
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3267-70. PubMed ID: 3196045
[TBL] [Abstract][Full Text] [Related]
13. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S.
De Stefano V; Simioni P; Rossi E; Tormene D; Za T; Pagnan A; Leone G
Haematologica; 2006 May; 91(5):695-8. PubMed ID: 16670075
[TBL] [Abstract][Full Text] [Related]
14. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.
Cancelas JA; García-Avello A; García-Frade LJ
Thromb Res; 1994 Sep; 75(5):513-20. PubMed ID: 7992252
[TBL] [Abstract][Full Text] [Related]
15. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
[TBL] [Abstract][Full Text] [Related]
16. Alpha-interferon in polycythemia vera and essential thrombocythemia.
Turri D; Mitra ME; Di Trapani R; Lipari MG; Perricone R; Cajozzo A
Haematologica; 1991; 76(1):75-7. PubMed ID: 2055565
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of specific thrombotic accidents in patients with thrombocytosis.
Randi ML; Fabris F; Tison T; Barbone E; Rossi C; Girolami A
Haematologia (Budap); 1993; 25(3):149-52. PubMed ID: 8119627
[TBL] [Abstract][Full Text] [Related]
18. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S.
Finazzi G; Barbui T
Thromb Haemost; 1994 Jan; 71(1):15-8. PubMed ID: 8165635
[TBL] [Abstract][Full Text] [Related]
19. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
20. Association of monoclonal gammopathy and polycythemia vera or essential thrombocythemia: study of a large cohort of patients.
Randi ML; Tison T; Ruzzon E; Pacquola E; Girolami A
Ann Hematol; 2003 Apr; 82(4):214-7. PubMed ID: 12707723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
